8-K 1 v474594_8k.htm FORM 8-K

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

August 29, 2017

Date of Report

 

TAPIMMUNE INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-37939   45-4497941
(State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)

 

5 West Forsyth Street, Suite 200

Jacksonville, FL

 

 

32202

(Address of principal executive offices)   (Zip Code)
     
904-516-5436    
(Issuer's telephone number)    

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 5.07SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

 

(a)   The 2017 annual meeting of shareholders of TapImmune Inc. (“TapImmune” or the “Company”) was held on August 29, 2017.

 

(b)   At the 2017 annual meeting, the following proposals were voted on by our shareholders:

 

PROPOSAL I:   Election of Directors.

 

Dr. Glynn Wilson, Mr. Mark Reddish, Ms. Sherry Grisewood, Mr. David Laskow-Pooley, Mr. Frederick Wasserman and Mr. Joshua Silverman were each re-elected as Directors, to serve until our next annual meeting of shareholders or until their respective successors are elected and qualified or until their earlier resignation, removal from office or death. The votes were as follows:

 

   For   Abstain/
Withheld
   Broker
Non-Votes
 
Dr. Glynn Wilson   3,378,404    148,471    3,398,085 
Mark Reddish   3,465,805    61,070    3,398,085 
Sherry Grisewood   3,488,540    38,336    3,398,084 
David Laskow-Pooley   3,487,548    51,104    3,386,398 
Frederick Wasserman   3,487,531    39,344    3,398,085 
Joshua Silverman   3,501,702    25,173    3,398,085 

 

PROPOSAL II: To conduct a non-binding advisory vote on executive compensation. The votes were as follows:

 

FOR   3,375,420 
AGAINST   133,768 
ABSTAIN/WITHHELD   17,687 
BROKER NON-VOTES   3,398,085 

 

PROPOSAL III: To conduct a non-binding advisory vote on the desired frequency of a non-binding vote on executive compensation. The votes were as follows:

 

ONE YEAR   2,738,325 
TWO YEARS   274,762 
THREE YEARS   508,569 
BROKER NON-VOTES   3,403,304 

 

As the Company’s Board of Directors recommended, and a majority of the votes cast approved, the Company will submit executive compensation to the shareholders on an annual basis until the issue of the frequency of such vote is again brought before the shareholders.

 

PROPOSAL IV: Approval of the Company’s 2014 Omnibus Stock Ownership Plan as amended through July 2017. The votes were as follows:

 

FOR   3,359,487 
AGAINST   147,696 
ABSTAIN/WITHHELD   19,692 
BROKER NON-VOTES   3,398,085 

 

 

 

 

PROPOSAL V: Approval of an amendment to the Company’s 2014 Omnibus Stock Ownership Plan as amended through July 2017 to increase the authorized shares by 800,000. The votes were as follows:

 

FOR   3,319,496 
AGAINST   173,470 
ABSTAIN/WITHHELD   33,909 
BROKER NON-VOTES   3,398,085 

 

PROPOSAL VI: Ratification of the selection of Marcum LLP as the Company’s independent auditors for the year ending December 31, 2017. The votes were as follows:

 

FOR   6,680,352 
AGAINST   181,968 
ABSTAIN/WITHHELD   62,640 

 

Item 9.01FINANCIAL STATEMENTS AND EXHIBITS.

 

(d)Exhibits

 

Exhibit No.

 

Description

 

10.1   2014 Omnibus Stock Ownership Plan, as amended through August 29, 2017

 

 

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 5th day of September, 2017.

 

  TAPIMMUNE INC.
  (Registrant)
       
  BY:  /s/ Michael Loiacono  
    Michael Loiacono  
    Chief Financial Officer